148 related articles for article (PubMed ID: 16480581)
1. [Correlation of cyclin D1 overexpression to mutations of von hippel-lindau gene in renal clear cell carcinoma].
Ren YY; Du LJ; Feng ZQ; Leng J
Ai Zheng; 2006 Feb; 25(2):175-8. PubMed ID: 16480581
[TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
3. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
4. Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas.
Atkins DJ; Gingert C; Justenhoven C; Schmahl GE; Bonato MS; Brauch H; Störkel S
Virchows Arch; 2005 Sep; 447(3):634-42. PubMed ID: 15991006
[TBL] [Abstract][Full Text] [Related]
5. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
Bindra RS; Vasselli JR; Stearman R; Linehan WM; Klausner RD
Cancer Res; 2002 Jun; 62(11):3014-9. PubMed ID: 12036906
[TBL] [Abstract][Full Text] [Related]
6. von Hippel-Lindau exonic methylation analysis using MALDI-TOF mass spectrometry.
Lian F; Sreedharan S; Arnold RS; Master VA; Ogan K; Pattaras JG; Roberts DL; Petros JA
J Urol; 2014 Nov; 192(5):1528-33. PubMed ID: 24704013
[TBL] [Abstract][Full Text] [Related]
7. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
9. High expression of the secreted protein dickkopf homolog 4: roles in invasion and metastasis of renal cell carcinoma and its association with Von Hippel-Lindau gene.
Zhai W; Hu GH; Zheng JH; Peng B; Liu M; Huang JH; Wang GC; Yao XD; Xu YF
Int J Mol Med; 2014 May; 33(5):1319-26. PubMed ID: 24573574
[TBL] [Abstract][Full Text] [Related]
10. VHL protein alterations in sporadic renal cell carcinoma.
Giménez-Bachs JM; Salinas-Sánchez AS; Sánchez-Sánchez F; Lorenzo-Romero JG; Donate-Moreno MJ; Pastor-Navarro H; Carrión-López P; Escribano-Martínez J; Virseda-Rodríguez JA
Clin Oncol (R Coll Radiol); 2007 Dec; 19(10):784-9. PubMed ID: 17919893
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
Ashida S; Okuda H; Chikazawa M; Tanimura M; Sugita O; Yamamoto Y; Nakamura S; Moriyama M; Shuin T
Clin Cancer Res; 2000 Oct; 6(10):3817-22. PubMed ID: 11051223
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
14. Novel mutations of the von hippel-lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type.
Meyer AJ; Hernandez A; Florl AR; Enczmann J; Gerharz CD; Schulz WA; Wernet P; Ackermann R
Int J Cancer; 2000 Sep; 87(5):650-3. PubMed ID: 10925357
[TBL] [Abstract][Full Text] [Related]
15. VHL tumor suppressor gene: its mutation and protein level in renal cell carcinoma.
Tsutsumi H; Miyamoto C; Furuichi Y; Yoshiike M; Nozawa S; Iwamoto T
Oncol Rep; 2003; 10(5):1357-61. PubMed ID: 12883707
[TBL] [Abstract][Full Text] [Related]
16. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
18. Sequencing of the von Hippel-Lindau gene in canine renal carcinoma.
Pressler BM; Williams LE; Ramos-Vara JA; Anderson KI
J Vet Intern Med; 2009; 23(3):592-7. PubMed ID: 19422471
[TBL] [Abstract][Full Text] [Related]
19. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
20. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
